It has been found that this block may reduce vital capacity by 50%, and this is why patients with associated lung diseases cannot tolerate it.
Se ha encontrado que este bloqueo puede disminuir la capacidad vital del paciente en un 50%, de ahí que pacientes con enfermedades pulmonares asociadas suelan no tolerarlo.